Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Myeloid, Acute 15Myelodysplastic Syndromes 10Recurrence 7Ovarian Neoplasms 7Multiple Myeloma 7Pancreatic Neoplasms 6Lymphoma 6Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Colorectal Neoplasms 5Burkitt Lymphoma 5Stomach Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hodgkin Disease 4Hematologic Neoplasms 4Sarcoma 3Osteosarcoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia, Biphenotypic, Acute 3Leukemia, B-Cell 3Leukemia 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Thymoma 2

Interventions

asciminib 2venetoclax 1gilteritinib 1fludarabine phosphate 1fludarabine 1blinatumomab 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Idarubicin 1Hyperbaric Oxygenation 1Filgrastim 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid × fludarabine × 30 days × Clear all
NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡